RNTX — Rein Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1420565 ·
Last close
$0.80
Market Cap
$69.01M
52W High
$1.17
52W Low
$0.69
ADV30
474,744
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,230,000 | -5,838,000 | 26,288,000 | 4,445,000 | 59,702,000 |
| Dec 2025 | 0 | — | -3,959,000 | -31,967,000 | 24,158,000 | 3,215,000 | 52,245,000 |
| Sep 2025 | 0 | — | -5,492,000 | -5,581,000 | 53,706,000 | 4,048,000 | 52,521,000 |
| Jun 2025 | 0 | — | -6,871,000 | -6,822,000 | 57,479,000 | 5,722,000 | 54,471,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-16,610,000
Investing CF
$0
Financing CF
$13,671,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.93
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-407,109,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-21,552,000
Pretax Income TTM
$-50,920,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -21,931,000 | -49,871,000 | 24,158,000 | 52,245,000 | — | -19,361,000 |
| Dec 2024 | 0 | -28,112,000 | -62,883,000 | 62,190,000 | 52,803,000 | — | -22,291,000 |
| Dec 2023 | 0 | -15,348,000 | -15,732,000 | 106,008,000 | 99,121,000 | — | -19,808,000 |
| Dec 2022 | 0 | -27,647,000 | -27,329,000 | 22,007,000 | 3,384,000 | — | -24,865,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TENX | TENAX THERAPEUTICS, INC. | $69.23M | $1.85 | — |
| PMVP | PMV Pharmaceuticals, Inc. | $69.76M | $1.30 | — |
| XBIT | XBiotech Inc. | $70.43M | $2.31 | — |
| IBIO | iBio, Inc. | $70.54M | $1.42 | — |
| PLRX | PLIANT THERAPEUTICS, INC. | $70.59M | $1.14 | — |
News headlines (Yahoo Finance, 1h cache)
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
2026-08-20 12:00 · Yahoo
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-14 10:44 · Yahoo
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
2026-08-04 12:00 · Yahoo
Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
2026-07-21 12:00 · Yahoo
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
2026-06-11 12:00 · Yahoo
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
2026-05-18 12:00 · Yahoo
Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock
2026-05-01 00:00 · Yahoo
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
2026-04-29 12:00 · Yahoo
All You Need to Know About Rein Therapeutics Inc. (RNTX) Rating Upgrade to Buy
2026-06-17 16:00 · Yahoo
Rein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary Fibrosis
2026-03-03 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.